Cargando…

The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy

BACKGROUND: Wolf-Hirschhorn syndrome is a well-characterized genomic disorder caused by 4p16.3 deletions. Wolf-Hirschhorn syndrome patients exhibit characteristic facial dysmorphism, growth retardation, developmental delay, intellectual disability and seizure disorders. Recently, NSD2 gene located w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xuyun, Wu, Di, Li, Yuchuan, Wei, Liya, Li, Xiaoqiao, Qin, Miao, Li, Hongdou, Li, Mengting, Chen, Shaoke, Gong, Chunxiu, Shen, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716467/
https://www.ncbi.nlm.nih.gov/pubmed/33276791
http://dx.doi.org/10.1186/s12920-020-00831-9
_version_ 1783619166713937920
author Hu, Xuyun
Wu, Di
Li, Yuchuan
Wei, Liya
Li, Xiaoqiao
Qin, Miao
Li, Hongdou
Li, Mengting
Chen, Shaoke
Gong, Chunxiu
Shen, Yiping
author_facet Hu, Xuyun
Wu, Di
Li, Yuchuan
Wei, Liya
Li, Xiaoqiao
Qin, Miao
Li, Hongdou
Li, Mengting
Chen, Shaoke
Gong, Chunxiu
Shen, Yiping
author_sort Hu, Xuyun
collection PubMed
description BACKGROUND: Wolf-Hirschhorn syndrome is a well-characterized genomic disorder caused by 4p16.3 deletions. Wolf-Hirschhorn syndrome patients exhibit characteristic facial dysmorphism, growth retardation, developmental delay, intellectual disability and seizure disorders. Recently, NSD2 gene located within the 165 kb Wolf-Hirschhorn syndrome critical region was identified as the key causal gene responsible for most if not all phenotypes of Wolf-Hirschhorn syndrome. So far, eight NSD2 loss of function variants have been reported in patients from different parts of the world, all were de novo variants. METHODS: In our study, we performed whole exome sequencing for two patients from one family. We also reviewed more NSD2 mutation cases in pervious literature. RESULTS: A novel loss of function NSD2 variant, c.1577dupG (p.Asn527Lysfs*14), was identified in a Chinese family in the proband and her father both affected with intellectual disability. After reviewing more NSD2 mutation cases in pervious literature, we found none of them had facial features that can be recognized as Wolf-Hirschhorn syndrome. In addition, we have given our proband growth hormone and followed up with this family for 7.5 years. CONCLUSIONS: Here we reported the first familial NSD2 variant and the long-term effect of growth hormone therapy for patients. Our results suggested NSD2 mutation might cause a distinct intellectual disability and short stature syndrome.
format Online
Article
Text
id pubmed-7716467
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77164672020-12-04 The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy Hu, Xuyun Wu, Di Li, Yuchuan Wei, Liya Li, Xiaoqiao Qin, Miao Li, Hongdou Li, Mengting Chen, Shaoke Gong, Chunxiu Shen, Yiping BMC Med Genomics Research Article BACKGROUND: Wolf-Hirschhorn syndrome is a well-characterized genomic disorder caused by 4p16.3 deletions. Wolf-Hirschhorn syndrome patients exhibit characteristic facial dysmorphism, growth retardation, developmental delay, intellectual disability and seizure disorders. Recently, NSD2 gene located within the 165 kb Wolf-Hirschhorn syndrome critical region was identified as the key causal gene responsible for most if not all phenotypes of Wolf-Hirschhorn syndrome. So far, eight NSD2 loss of function variants have been reported in patients from different parts of the world, all were de novo variants. METHODS: In our study, we performed whole exome sequencing for two patients from one family. We also reviewed more NSD2 mutation cases in pervious literature. RESULTS: A novel loss of function NSD2 variant, c.1577dupG (p.Asn527Lysfs*14), was identified in a Chinese family in the proband and her father both affected with intellectual disability. After reviewing more NSD2 mutation cases in pervious literature, we found none of them had facial features that can be recognized as Wolf-Hirschhorn syndrome. In addition, we have given our proband growth hormone and followed up with this family for 7.5 years. CONCLUSIONS: Here we reported the first familial NSD2 variant and the long-term effect of growth hormone therapy for patients. Our results suggested NSD2 mutation might cause a distinct intellectual disability and short stature syndrome. BioMed Central 2020-12-04 /pmc/articles/PMC7716467/ /pubmed/33276791 http://dx.doi.org/10.1186/s12920-020-00831-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Hu, Xuyun
Wu, Di
Li, Yuchuan
Wei, Liya
Li, Xiaoqiao
Qin, Miao
Li, Hongdou
Li, Mengting
Chen, Shaoke
Gong, Chunxiu
Shen, Yiping
The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy
title The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy
title_full The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy
title_fullStr The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy
title_full_unstemmed The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy
title_short The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy
title_sort first familial nsd2 cases with a novel variant in a chinese father and daughter with atypical whs facial features and a 7.5-year follow-up of growth hormone therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716467/
https://www.ncbi.nlm.nih.gov/pubmed/33276791
http://dx.doi.org/10.1186/s12920-020-00831-9
work_keys_str_mv AT huxuyun thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT wudi thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT liyuchuan thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT weiliya thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT lixiaoqiao thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT qinmiao thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT lihongdou thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT limengting thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT chenshaoke thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT gongchunxiu thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT shenyiping thefirstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT huxuyun firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT wudi firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT liyuchuan firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT weiliya firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT lixiaoqiao firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT qinmiao firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT lihongdou firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT limengting firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT chenshaoke firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT gongchunxiu firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy
AT shenyiping firstfamilialnsd2caseswithanovelvariantinachinesefatheranddaughterwithatypicalwhsfacialfeaturesanda75yearfollowupofgrowthhormonetherapy